Form 4: Kiniksa Pharmaceuticals Director Trades Class A Shares
Insider Transaction Report
Director G. Bradley Cole reported transactions involving Class A Ordinary Shares and derivative securities of Kiniksa Pharmaceuticals International, plc.
Summary
- G. Bradley Cole, a Director at Kiniksa Pharmaceuticals International, plc, reported several transactions on May 29, 2026.
- These transactions include the acquisition of 2,799 Class A Ordinary Shares.
- Cole also acquired 12,158 share options with an exercise price of $48.38, exercisable starting May 29, 2026, and expiring May 28, 2036.
- Additionally, 2,026 Restricted Share Units (RSUs) were acquired, and 2,799 RSUs vested on the same date.
- Following these transactions, Cole beneficially owns 15,345 Class A Ordinary Shares directly.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral filing, as it reports routine insider transactions related to compensation and equity awards rather than significant strategic or financial performance indicators.
Positives
- Director G. Bradley Cole acquired additional Class A Ordinary Shares, indicating continued investment or compensation.
- The acquisition of share options suggests potential future upside for the director tied to the company's stock performance.
- Vesting of RSUs on May 29, 2026, represents a realization of equity compensation for the director.
Future Outlook
The filing does not contain forward-looking statements or guidance. It solely reports on past transactions.
Industry Context
StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions in the pharmaceutical sector, providing transparency on executive compensation and investment.
Stakeholder Impact
- Shareholders: Increased transparency into director's equity holdings and compensation structure.
- Employees: May provide insight into the company's equity-based compensation practices.
- Management: Standard reporting requirement for directors.
Key Dates
| Date | Description |
|---|---|
| 05/29/2026 | Earliest transaction date reported, date of acquisition of shares, options, and RSUs, and vesting of RSUs. |
| 05/28/2036 | Expiration date for share options. |
| 06/02/2026 | Date the Form 4 was signed by the attorney-in-fact. |
| 09/18/2025 | Date the Power of Attorney was executed. |
Keywords
Kiniksa Pharmaceuticals, KNSA, Form 4, Director, Class A Ordinary Share, Share Options, Restricted Share Units, Beneficial Ownership, SEC Filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.